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four clusters (cluster 1  UK, Denmark, Norway, Nether-
lands; cluster 2  Germany, Finland; cluster 3  Belgium;
cluster 4  France). In the multilevel model, variances were
observed operating at the different levels which could be ex-
plained in terms of the general characteristics of the sites.
CONCLUSIONS: The results of this analysis suggest that
cluster analysis and multilevel modeling techniques can
be valuable tools in the exploration of multinational eco-
nomic data, although they require considerable care in
practice. The presence of clustering may have important
implications for costing and the pooling of multinational
economic evaluation data.
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PRICE ELASTICITY OF PEOPLE’S 
WILLINGNESS TO PAY IN PATIENTS WITH 
URINARY INCONTINENCE
Budhiarso I, Bushnell DM
Health Research Associates, Inc., Seattle, WA, USA
OBJECTIVES: The purpose of this study was to evaluate
the impact of price change on the willingness to pay
(WTP) of patients with urinary incontinence.
METHODS: A sample of 41 women with urinary incon-
tinence (UI) from Seattle and Philadelphia were inter-
viewed. The questionnaire contained a WTP question
with 11 bids ranging from $1 to $200. Two versions of
the questionnaire were administered, one for “improve-
ment” and one for “cure.” Respondents recorded whether
they would accept or reject each bid (“price”) at the
stated dollar value. The analysis was conducted using the
modified price elasticity concept defined by the percent
change in the number of people who were willing to pay
divided by the percent change in price.
RESULTS: Elasticity comparison between improvement
and cure showed that, in general, people’s WTP was
more “elastic” for improvement than it was for cure. In
the lower price range (from $10 to $50), the WTP for both
improvement and cure were inelastic (elasticity less than
one). For the higher price range ($50 to $200), only WTP
for improvement showed elasticity greater than one.
CONCLUSIONS: Regardless the price range, people are
more sensitive to the price change for a scenario promising
“improvement” than they are for “cure.” Therefore,
changes in price affect patients’ WTP for improvement
more than it will for cure. For a price range up to $50,
people will react similarly to price changes for both “im-
provement” and “cure.” People will react differently,
however (more elastic to improvement) at a price range
greater than $50. Therefore, the issue of the treatment out-
come (improvement versus cure) has a notable impact on
patient WTP when costs to them exceed $50.
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OSTEOPOROSIS MARKOV MODEL: 
EVALUATING THE IMPACT OF DISCOUNTING 
AND AGE-ADJUSTED FRACTURE RATES
ON COST-EFFECTIVENESS RATIOS AND 
MARKOV ANALYSIS
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With the ongoing discussion about whether both costs
and outcomes should be discounted, alternate model con-
struction reflecting these options can be very informative.
Furthermore, the area of osteoporosis would dictate that
age adjusted fracture rates would be a particularly influ-
ential component to consider in model construction.
OBJECTIVE: This analysis reports the impact of step-
wise inclusion of the discounting costs and outcomes and
an age-adjustment on increment cost-effectiveness ratios.
METHODS: The two alternatives included hormone re-
placement therapy with calcium supplementation com-
pared with calcium supplementation alone in a cohort of
women age 50 to 90 years. The effectiveness measure
was fractures avoided.
RESULTS: The base model discounts only costs with no
age-adjustment for fracture rates (incremental CER:
$56,178.16, favoring hormone therapy). The model dis-
counting both costs and outcomes with no age-adjustment
for fracture rates, resulted in an incremental CER of
$37,817.38 per fracture avoided. Age-adjustment of frac-
ture rates resulted in incremental CER of $83,561.59 per
fracture avoided (discounted costs only) and $42,232.68
per fracture avoided (discounted costs and outcomes). All
models favored hormone replacement therapy and did
not result in any decision changes. At the end of 40 years,
Markov analysis demonstrated that age-adjustment of
fracture rates induced a shift to more desirable states. The
most dramatic shift was 14.87 and 5.15 more women out
of 1000 alive with no fracture in the hormone and calcium
arms, respectively.
CONCLUSION: The effect of discounting did not
change the decision outcome of the osteoporosis Markov
model. However, the magnitude of the change in Markov
state composition was dramatic as a result of the age ad-
justment to fracture rates.
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Tailoring the results from clinical trials and associated
pharmacoeconomic analyses to specific populations is
frequently requested by managed care companies. Mod-
els based on clinical trials and analyses often use pub-
lished results that typically present only study means (or
means and variances). However, underlying distributions
of results are not always normally or uniformly distrib-
uted, leading to potentially biased model predictions.
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OBJECTIVE: This study aims to describe the distributions
of lipid lowering and attainment of National Cholesterol
Education Panel goals and apply these distributions to
pharmacoeconomic models for specific populations.
METHODS: Lipid results and costs from a series of
treat-to-target studies of statins (atorvastatin, fluvastatin,
lovastatin, pravastatin, and simvastatin) were used to es-
timate distributions of lipid-lowering effects and cost for
patients.
RESULTS: Almost 1000 patients were enrolled in one of
three trials: patients with risk factors for coronary heart
disease (CHD) in the United States, CHD in the United
States, and CHD or peripheral vascular disease (PVD) in
Europe. Lipid-lowering effects are not normally distrib-
uted and are not consistent among statins. Results for
two statins were skewed right and results for three statins
were skewed left. As a result, costs associated with lipid-
lowering treatment are not normally distributed and are
not equal among statins.
CONCLUSIONS: Models based upon clinical and trials
and associated pharmacoeconomic analyses may be biased
if they use only published data without an understanding
of the underlying distributions of these data. In a set of
populations with higher than average lipid levels (lower
than average lipid levels), models that rely on means from
published studies would underestimate (overestimate) the
differences among statins.
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EFFECT OF DEMOGRAPHICS ON THE COST 
OF PHARMACEUTICALS IN A PRIVATE 
THIRD-PARTY PRESCRIPTION PROGRAM
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OBJECTIVES: The primary objective of this study was to
compare variance in cost of pharmaceuticals explained
by demographic variables with variance explained by
plan-characteristics within various therapeutic categories
using prescription claims data. The secondary objective
was to examine differences in utilization among demo-
graphic variables after controlling for covariates.
METHODS: Data were obtained from 1996 prescription
claims information for the commercial population ad-
ministered by a Rhode Island–based PBM. There were
29,211 subscribers representing 64,815 enrollees (mean
age 31.5) eligible during 1996. Subscribers were mainly
employed in health (39.8%), sales and services (17.7%),
and manufacturing (10.3%). Six therapeutic categories
were analyzed. Statistical analyses utilizing multiple re-
gression and analysis-of-covariance were performed.
RESULTS: Plan-characteristics out-performed demographic
variables 16-fold for all drug categories combined in ex-
plaining variance in cost of pharmaceuticals. Significant
differences (p  0.0001) in utilization were found among
demographic variables after controlling for average whole-
sale price and days supply.
CONCLUSIONS: The results obtained in this study have
practical significance in the determination of capitation
rates when utilization history of prospective members is un-
available. In this situation, PBMs may have to set capita-
tion rates based solely on eligibility data. PBMs contract
with commercial clients to provide pharmacy benefits to
their employees irrespective of their occupation. Significant
differences in utilization among the members based on
place of employment suggest that benefit managers should
consider differentiating capitation rates according to their
clients’ businesses. Finally, this study indicated that com-
mercial members residing in Tennessee had the lowest level
of drug utilization among all states evaluated. The fact that
one PBM manages over 80% of the TennCare prescription
program along with a significant commercial client base
suggests that “spillover-effect” may exist.
DP2
THE RELATIONSHIP BETWEEN PAYER TYPE 
AND HOSPITALIZATION RATES FOR 
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OBJECTIVE: Hospitalization is the single greatest cost in
the treatment of asthma. Various factors, such as type of
healthcare insurance, may be related to asthma hospital-
ization rates. This study assessed the hospitalization rates
for asthmatics subsequent to an emergency room (ER)
visit among payer types.
METHODS: Medical claims from the Premier PCD data-
base were screened to identify adults (ages 18–65) visit-
ing an ER for treatment of asthma (ICD-9-CM: 493)
from October 1, 1996 to September 30, 1997. Subjects
were then classified into two groups: ER only and ER
and hospitalization. Payers identified from each claim
were grouped into these categories: Managed Care, In-
demnity Plans, Medicaid, Medicare, and Self-Pay.
RESULTS: Of the 2738 patients who met the inclusion
criteria, only 773 (28%) required hospitalization. Self-
Pay patients were the least likely to be hospitalized
(12.6% hospitalization rate) while Indemnity and Man-
aged Care patients were hospitalized at a rate of 23.4%
and 33.3%, respectively. After controlling for age, race,
gender, and comorbidities, Indemnity patients were ap-
proximately 65% as likely to be hospitalized as Managed
Care patients (OR  0.650; 95% CI 0.493–0.856). Of
the hospitalized patients, the Self-Pay patients had the
shortest hospital stay and lowest total cost (2.98 days,
$2417.72). Managed Care patients had lower total costs
and shorter hospital stays than Indemnity patients, how-
ever the differences among the groups were not signifi-
cant. No significant differences in mean age or APR-DRG
